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Abstract
Aims/hypothesis Per-Arnt-Sim kinase (PASK) is a nutrient-
regulated domain-containing protein kinase previously impli-
cated in the control of insulin gene expression and glucagon
secretion. Here, we explore the roles of PASK in the control of
islet hormone release, by generating mice with selective dele-
tion of the Pask gene in pancreatic beta or alpha cells.
Methods Floxed alleles of Pask were produced by homolo-
gous recombination and animals bred with mice bearing beta
(Ins1Cre; PaskBKO) or alpha (PpgCre [also known as Gcg];
PaskAKO) cell-selective Cre recombinase alleles. Glucose
homeostasis and hormone secretion in vivo and in vitro, gene
expression and islet cell mass were measured using standard
techniques.
Results Ins1Cre-based recombination led to efficient beta cell-
targeted deletion of Pask. Beta cell mass was reduced by
36.5% (p<0.05) compared with controls in PaskBKO mice,
as well as in global Pask-null mice (38%, p<0.05). PaskBKO
mice displayed normal body weight and fasting glycaemia,
but slightly impaired glucose tolerance, and beta cell prolifer-
ation, after maintenance on a high-fat diet. Whilst glucose
tolerance was unaffected in PaskAKO mice, glucose infusion
rates were increased, and glucagon secretion tended to be
lower, during hypoglycaemic clamps. Although alpha cell
mass was increased (21.9%, p<0.05), glucagon release at
low glucose was impaired (p<0.05) in PaskAKO islets.
Conclusions/interpretation The findings demonstrate cell-
autonomous roles for PASK in the control of pancreatic endo-
crine hormone secretion. Differences between the glycaemic
phenotype of global vs cell type-specific null mice suggest
important roles for tissue interactions in the control of
glycaemia by PASK.
Francesca Semplici and Gabriela da Silva Xavier contributed equally to
this study.
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Introduction
Type 2 diabetes affects approximately one in 12 of the adult
population [1] and usually involves changes in both insulin se-
cretion [2] and insulin action [3]. Acting on the healthy pancreatic
beta cell, elevated blood glucose concentrations lead to increased
glucose flux across the plasmamembrane, mediated by the trans-
porter GLUT2 (plus GLUT1 in humans) [4], glucose phosphor-
ylation catalysed by glucokinase, and enhanced glycolytic flux to
fuel the citrate cycle [5]. Increasedmitochondrial metabolism [6],
ATP synthesis [7] and the closure of ATP-sensitive K+ channels
[8] cause plasma membrane depolarisation, Ca2+ influx via
voltage-gated channels (L-type) [9], the further activation of mi-
tochondrial metabolism [10], and secretory granule exocytosis
[11]. In addition, ATP-sensitive K+ channel-independent mecha-
nisms potentiate the actions of Ca2+ via mechanisms that are
presently poorly understood [12]. The signalling pathways con-
trolling glucagon secretion are less well defined and may involve
a more dominant role for neural and hormonal control [13], as
well as the cell-intrinsic actions of glucose. Enhanced ATP syn-
thesis [14], ATP-sensitive K+ channel closure and the opening of
T-type Ca2+ channels [15], and ATP-dependent effects on intra-
cellular Ca2+ stores may also be involved [16].
Fuel-sensing kinases such as AMP-activated protein kinase
[17] have previously been implicated in the control of both
insulin [18, 19] and glucagon secretion [20, 21]. Originally
cloned in 2001 by Hofer and colleagues [22] and, separately,
by Rutter and colleagues [23], Per-Arnt-Sim (PAS) domain-
containing protein kinase (PASK, also known as PASKIN) is a
member of the nutrient-regulated protein-serine kinase family
and the only PAS domain-containing member of this group
expressed in mammalian cells [24]. In Saccharomyces
cerevisiae there are two PASK orthologues: Psk1 and Psk2.
Under cell wall stress conditions these enzymes phosphorylate
the metabolic enzyme uridine diphosphate-glucose pyrophos-
phorylase to mobilise glucose [25]. Importantly, the PAS
domain of the mammalian enzyme is potentially targetable
by small molecules and as such may offer an attractive target
for therapeutic intervention in some forms of diabetes [24].
Implying a potentially important role for PASK in regulat-
ed insulin secretion, we showed in 2004 that PASK is required
in clonal pancreatic beta cells for normal proinsulin gene ex-
pression [26]. Subsequently, Rutter and colleagues [27] dem-
onstrated a role for PASK in mammalian glucose homeostasis
by showing that mice deleted globally for the enzyme
displayed improved insulin sensitivity but impaired insulin
secretion in vivo and from isolated islets. We have also shown
that activating mutations in the human PASK gene modulate
insulin secretion [28]. However, subsequent studies [29]
revealed little effect of global Pask deletion in mice on
in vivo insulin secretion, but a profound effect on total pan-
creatic insulin content, consistent with a role for PASK in
insulin gene expression [26, 29, 30] and insulin protein stabil-
ity [31]. Glucagon release was enhanced in this model [29].
The impact of tissue-selective deletion of conditional Pask
alleles has not hitherto been explored, restricting our under-
standing of the role of the kinase in glucose homeostasis
in vivo. Here, we describe the generation of floxed alleles of
the kinase and explore the impact of its deletion from pancreatic
beta or alpha cells. Whereas fasting and fed insulin levels and
glucose-stimulated insulin secretion were not affected by Pask
deletion under most conditions, beta cell mass was significantly
(36.5%) reduced in beta cell-selective null animals (PaskBKO).
On the other hand, alpha cell-selective deletion (PaskAKO) led
to impaired glucagon secretion in vitro and in vivo. These find-
ings demonstrate the importance of PASK for the normal de-
velopment and function of the beta and alpha cell, respectively.
Methods
Generation ofPaskBKOand PaskAKOmiceMice carrying
conditional null alleles of Pask (Paskfl/fl) were generated
Fig. 1 Generation of conditional Pask alleles and deletion in beta or alpha
cells. (a) Knockout (KO) strategy. Generation of beta (PaskBKO) and alpha
(PaskAKO) cell-specific PaskKOmice by Cre-mediated excision of exons
from 12 to 15 encoding the PASK Ser/Thr kinase domain. Human PASK
cDNA (modified from [22]) with the Ser/Thr kinase domain encoding
exons circled in purple and enlarged in the black box—a view from the
back of PASK kinase domain (amino acids 977–1300) crystal structure
(PBD code 3DLS) with the bound ADP molecule in evidence [43].
(b) Mouse Pask gene structure (modified from [22]) and the location of
the loxP sites. (c) Example of a genotyping gel indicating the presence of
WT and recombined (Cond) alleles. (d) Pask and Ins2 gene expression
measured by qPCR in PaskBKO (BKO) and control (WT) mouse islets.
Immunohistochemical analysis of pancreatic sections from PaskBKO
(e) and PaskAKO (f) mice and controls, with PASK revealed using Alexa
568 (red), and insulin or glucagon revealed using Alexa 488 (green). Insets
i–iv are magnified areas, as shown in the main images. Insets v–viii are
example images of no-primary-antibody controls for each of the genotypes,
with insets v and vii showing the DAPI staining for nuclei; scale bars,
100 μm. PASK fluorescence was displayed in 87.6 ± 1.5% of insulin-
positive cells in WT islets vs 10.5 ± 2.3% in PaskBKO islets; n=7 mice
per genotype for both PaskBKO and PaskAKO mice; *p < 0.05 and
**p < 0.01 by Student’s t test. Data were obtained by counting pixel
overlay from ten pancreatic slices (typically counting approximately ten
islets per slice) per mouse using Fiji (see ESM Methods)
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by insertion of loxP sites flanking exon 11 and exon 15,
which encompass the Ser/Thr kinase domain, through
homologous recombination (see electronic supplementary
material [ESM] Methods, ESM Fig. 1a–c).
Paskfl/fl mice were crossed with animals expressing
Cre recombinase under the control of the insulin 1 pro-
moter (Ins1Cre mice [32]) or with mice expressing Cre
under the control of the glucagon promoter (PpgCre
1940 Diabetologia (2016) 59:1938–1947
mice [33]) to achieve deletion in pancreatic beta cells
(PaskBKO) or in pancreatic alpha cells (PaskAKO).
PaskBKO mice were born at the expected Mendelian
ratios. PaskAKO mice were born at the expected
Mendelian ratios only if assuming that the Cre trans-
gene had co-localised on the same chromosome (chro-
mosome 1) as the Pask floxed gene. Genotyping was
performed by PCR using DNA from ear biopsies.
Ablation of Pask gene expression from pancreatic islets
was assessed by quantitative real-time PCR (qPCR) on
cDNA reverse-transcribed from islet RNA, as described
below. All mouse strains were maintained on a C57BL/
6 background. Mice with global deletion of Pask [34]
were gifts from R. Wenger (University of Zürich,
Zürich, Switzerland).
Mouse maintenance and diet Animals were housed in
groups of two to five per individually ventilated cage
in a pathogen-free facility with a 12 h light/dark cycle
and were fed ad libitum with a standard mouse chow
diet or a high-fat diet (60% wt/wt fat content; Research
Diets, New Brunswick, NJ, USA). Where indicated,
8-week-old mice were transferred on to a high-fat diet
for a period of 12 weeks. All in vivo procedures de-
scribed were performed at the Imperial College Central
Biomedical Service and approved by the UK Home
Office according to the UK Animals (Scientific
Procedures) Act 1986 (PPL 70/7349 and PPL 70/7179).
In vivo physiology (IPGTT, in vivo glucose-
stimulated insulin secretion, insulin tolerance tests, plas-
ma glucagon, hyperinsulinaemic–hypoglycaemic
clamps), RNA extraction and qPCR, islet isolation and
hormone secretion, and beta and alpha cell mass mea-
surements are described in ESM Methods. Blood was
collected at indicated time points and plasma insulin
was measured by ELISA (Mercodia, Uppsala, Sweden).
Total cellular RNA was extracted from mouse islets or
other tissues and converted to cDNA for qPCR. Alpha
and beta cell mass was assessed in pancreases from
20-week-old mice. Anti-PASK antibody (PA5-29309;
Pierce, Rockford, IL, USA) was used in immunohisto-
chemical analysis. Experimenters were blinded to the
group assignment for assessment of islet cell mass.
Samples were not randomised. No data, samples or an-
imals were excluded.
Statistical analysis Data are expressed as means ± SEM.
Significance was tested by unpaired or paired two-
sample Student’s t tests using Excel, or by ANOVA
using GraphPad 4.0 (La Jolla, CA, USA). A value of
p< 0.05 was considered significant.
Results
Generation of mice deleted for PASK selectively in the
pancreatic beta or alpha cell Breeding of mice with floxed
Pask alleles with animals expressing Cre recombinase under
the control of the Ins1 [32] or Ppg gene promoter [33] was
predicted to lead to recombination selectively in pancreatic
islet beta (PaskBKO) or alpha (PaskAKO) cells, respectively.
Correspondingly, Pask mRNA levels, assessed by qPCR,
were reduced by >75% in PaskBKO mouse islets vs controls
(Fig. 1d, left), with concomitant reduction in beta cell PASK
protein content, as assessed by immunohistochemistry
(Fig. 1e). No change in Ins2 mRNA levels (Fig. 1d, right)
was detected in the same islets. By contrast, differences in
Pask mRNA could not be detected between PaskAKO and
wild-type (WT) islets (not shown), likely reflecting the low
abundance of alpha cells in rodent islets (~20% of all cells)
[35] and expected 20–50% deletion with the PpgCre used here
[21]. Correspondingly, in PaskAKO islets, immunohisto-
chemical analysis revealed a 42.6±17.5% overlap of the sig-
nal from anti-PASK antibody with that from glucagon anti-
body, whereas this value was close to 100% in WT islets
(Fig. 1f).
Pancreatic PaskBKO slightly impairs glucose homeostasis
after high-fat feeding Measured in male mice at 8 and
20 weeks of age, PaskBKO animals on a normal chow diet
displayed normal weight gain (Fig. 2a) and normal glucose
homeostasis during IPGTT compared with WT littermates
(Fig. 2b, c). Both in vivo (1 g/kg; Fig. 3a, b) and in vitro
(Fig. 3c) glucose-stimulated insulin secretion were unaffected
by the deletion of Pask.
In order to provide a metabolic stress on the beta cell,
where effects of Pask deletion might become apparent, we
challenged PaskBKO mice with a high-fat diet for 12 weeks.
Weight gain between WT and null mice was not significantly
different (Fig. 2d). PaskBKO animals exposed to a high-fat
diet had an elevated glucose peak during IPGTT compared
with WT littermates (Fig. 2e), although no significant differ-
ences in AUC for glucose excursions (Fig. 2e) or plasma in-
sulin (Fig. 3a, b) were observed.
Pancreatic beta cell mass is lowered in PaskBKOmice and
global Pask-null mice The above observations suggested that
beta cell function or mass may be affected by Pask deletion.
Since a beta cell phenotype may be masked or compensated for
in vivo, we further investigated this in detail by performing
in vitro experiments and by quantifying islet mass. To explore
the latter possibility, optical projection tomography or immuno-
histochemistry were undertaken and revealed a 36.5±1.2%
(Fig. 4a–d) and a 38±1.93% (Fig. 4e) decrease in beta cell
mass in PaskBKO and global Pask-null mice, respectively. In
PaskBKO animals, this reflected both increases in the number
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of smaller, and decreases in the number of larger, islets
(Fig. 4d). Interestingly, after maintenance on a high-fat diet,
we observed a similar decrease in beta cell mass (Fig. 5c), as
well as a near-complete elimination of Ki-67 staining, in beta
cells of PaskBKO vs WT islets (Fig. 5a, b and d), indicating
impaired proliferation under these conditions. Fed plasma insu-
lin levels were, nonetheless, unchanged in this model (Fig. 5e).
Pancreatic alpha cell mass is lowered in global
Pask-null mice but increased in PaskAKO mice
Immunohistochemical analysis revealed a 47.4 ± 0.7% de-
crease in alpha cell mass in global Pask-null mice (Fig. 4g).
Whilst no significant changes in beta cell mass were observed
in PaskAKOmice (Fig. 6a–c), a 21.9±4.6% increase in alpha
cell mass was detected in PaskAKO vs WT mice (Fig. 6d).
Abnormal counterregulatory responses and glucagon
secretion in PaskAKO miceMale PaskAKO mice on a nor-
mal chow diet or a high-fat diet showed no significant differ-
ences in weight gain or glucose tolerance between 8 and
20 weeks (Fig. 2f–j).
We performed hyperinsulinaemic–hypoglycaemic clamps
to explore the impact of deleting Pask in the alpha cell on
in vivo glucagon production. Strikingly, upon insulin infusion,
the decrease in glycaemia was more rapid in PaskAKO
Fig. 3 PaskBKO mice display normal glucose-stimulated insulin secre-
tion both in vivo after intraperitoneal glucose injection and in vitro from
isolated islets. (a, b) In vivo glucose-stimulated insulin secretion: 13- to
15-week-old mice [PaskBKO (BKO), dashed black line on line graph or
white column on histogram, male (a) n= 4, female (b) n= 5; WT, solid
black line on line graph or black bar on histogram, male (a) n= 5, female
(b) n = 6] were injected with 3 g glucose/kg body weight. (c) In vitro
glucose-stimulated insulin secretion from islets isolated from PaskBKO
(white columns, n= 4) and WT (black columns, n= 4) mice at 3 mmol/l
and 17 mmol/l glucose (G) or 3 mmol/l glucose plus 20 mmol/l KCl.
Statistical comparisons were made using one-wayANOVA; ***p< 0.001
Fig. 2 PaskBKO, but not PaskAKO,mice on a high-fat diet display mild
glucose intolerance after i.p. glucose injection. Body weight (a, f) and
IPGTT for PaskBKO (blue), PaskAKO (red) and WT (black) male mice
on a normal chow diet at (b, g) 8 weeks, and at (c, h) 20 weeks. Body
weight (d, i) and IPGTT for PaskBKO (blue), PaskAKO (red) and WT
(black) male mice on a high-fat diet at (e, j) 20 weeks; n= 7 for each
genotype; *p < 0.05 by Student’s t test with Bonferroni correction; AUCs
(insets) given in arbitrary units
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animals vs WT mice, with the former reaching 0.5 g/l at
around 40 min compared with 60 min in controls (Fig. 7a).
Furthermore, during the time period 60–120 h, when
glycaemia was similar in both groups (around 0.5 g/l), it was
necessary to infuse more glucose in PaskAKO mice,
confirming a likely lack of counterregulatory response in these
mice (Fig. 7b). Although a small but significant increase in
glucagon levels was apparent prior to the onset of the glucose
clamps (Fig. 7c), glucagon release at 120 min displayed a
strong tendency towards a lowering in the knockout mice
(Fig. 7c). Similarly, glucagon secretion from isolated islets
was significantly reduced in response to low glucose
(Fig. 7d). By contrast, we observed no differences in insulin
tolerance between mice of either genotype in vivo (Fig. 7e).
Discussion
We provide here the first description of mice deleted highly
selectively for Pask in the pancreatic alpha or beta cell.
We were able to demonstrate a robust lowering of Pask
expression in islets in both PaskBKO and PaskAKO mice,
reflecting the expected efficiency of the Ins1Cre deleter strain
(found to recombine in >94% of beta cells, with no significant
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in PaskBKO and global Pask-null
mice. Beta cell volume was
measured by optical projection
tomography, as described in the
Methods section. Representative
images of pancreases from WT
(a) and PaskBKO (b) mice are
shown, with insulin staining in
green; scale bar, 500 μm.
Quantification of beta cell relative
to total pancreas volume (c) and
size distribution of islets
(d); PaskBKO in white, WT in
black. (e, g) Beta and alpha cell
mass and (h) plasma insulin levels
after an IPGTT in global
Pask-null mice (KO, white
columns or dotted line; WT in
black columns or solid line) were
assessed by wide-field
microscopy and following
immunohistochemistry,
respectively. (f) Representative
images of pancreatic sections
from WT and global Pask-null
mice; scale bar, 1000 μm. Data
were from at least four mice per
genotype, aged 20 weeks;
*p ≤ 0.05 by Student’s t test with
Bonferroni correction for multiple
tests
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off-target recombination in other cell types) [32, 36] and the
PpgCre strain (which recombines in 20–50% of alpha cells)
[37].
Role of PASK in the beta cellWhilst insulin secretion from
islets was previously shown to be defective in global
Pask-null mice [27], our own studies with this model [29]
indicated that the stimulation of insulin release was normal.
However, Ins2 and Pdx1 gene expression were both substan-
tially lower in knockout islets, and the pancreatic content of
the hormone was sharply reduced [29]. In the present study
using the Ins1Cre line [36, 38] to inactivate Pask in the beta
cell, we did not detect decreases in insulin mRNA measured
per islet, but did observe a significant lowering of beta cell
mass throughout the pancreas (Fig. 4c, d), which was
paralleled by decreased Ki-67 immunoreactivity when mea-
sured after a high-fat diet (Fig. 5a–d). Furthermore, in vivo
measurements of insulin revealed no significant decreases in
plasma insulin following an IPGTT in PaskBKO mice when
measured at 13–15 weeks (Fig. 3a, b), although there was a
tendency towards lowered plasma insulin when measured
between 16 and 20 weeks (data not shown). By contrast, glob-
al Pask-null mice displayed both decreases in beta cell mass
(Fig. 4e) and in vivo insulin secretion (Fig. 4h).
The reason(s) for the modest effect of beta cell-specific
elimination of PASK, in contrast to findings in the global
Pask-null mouse here and in earlier reports [26, 29–31], is
unclear. However, these results may suggest that changes in
the global Pask-null mice reflect either (1) a requirement for
PASK during the development of beta cell progenitors, and/or
(2) the downstream consequences of Pask deletion elsewhere
in the body, possibly including the brain [39]. With respect to
the first, Semache and colleagues [31] have previously report-
ed that PASK regulates the stability of pancreatic duodenal
homeobox 1, a key regulator of the insulin gene [40], which
might be expected to restrict beta cell development and may
underlie an observed decrease of ~37% beta cell mass in the
PaskBKO mouse found here. Of note, such a decrease is not
expected to induce glucose dyshomeostasis, given that the
destruction of 50% of beta cells is without effect in mice
[41]. Thus, impaired glucose intolerance in PaskBKO mice
after a high-fat diet is likely to reflect additional changes to
pancreatic beta cell function and glucose sensing.
Role of PASK in the alpha cell Our previous findings [29]
pointed to a role for PASK in the control of glucagon secre-
tion. Here, we demonstrate this role in vivo after selective
WT BKO
*
0
2
4
6
8
10
12
14
0
0.2
0.4
0.6
0.8
1.0
1.2
WT KO
WT KO
WT KO
*
0
50
100
150
200
250
B
et
a 
ce
ll 
vo
lu
m
e 
(%
)
K
i-6
7/
be
ta
 c
el
l
vo
lu
m
e 
(%
) 
P
la
sm
a 
in
su
lin
(p
m
ol
/l)
 
a
c
e
d
b
Fig. 5 PaskBKO islets from mice that have been exposed to a high-fat
diet have lowered beta cell mass and Ki-67 immunoreactivity. Ki-67
levels (revealed using Alexa 568, red) and insulin (revealed using
Alexa 488, green) were assessed by immunohistochemistry, as described
in the Methods section. Blue indicates DAPI staining for nuclei.
Representative images of islets from WT (a) and PaskBKO (b) islets
and quantification of beta cell mass (c) are shown. Ki-67 expression is
shown as a percentage of beta cell volume (d). Plasma insulin content is
shown in (e). Arrows indicate Ki-67 staining (a); scale bar, 50 μm;
*p ≤ 0.05 by Student’s t test with Bonferroni correction
Fig. 6 PaskAKO mice display increased alpha cell mass.
Immunohistochemical analysis of pancreases from male PaskAKO mice
at 20 weeks of age was performed as described in the Methods section.
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deletion from the alpha cell population. Unexpectedly, whilst
we confirmed our previous finding of enhanced basal release
of the hormone in global Pask-null mice (Fig. 7c), suggesting
that PASK restricts glucagon release at normal levels of
glycaemia, we now demonstrate that PASK is required for
the stimulation of glucagon release during hypoglycaemia.
Thus, glycaemia was lowered more rapidly in response to
insulin infusion in PaskAKO mice than in controls, despite
higher glucose infusion rates (Fig. 7). Of note, these changes
were apparent despite deletion in 57.4% of alpha cells with the
Cre deleter strain used here [21, 37]. Given the observed de-
crease in alpha cell mass of ~47% in the global Pask-null
mouse (Fig. 4g), we hypothesised that decreases in alpha cell
number may contribute to impaired glucagon production in
PaskAKO mice. However, PaskAKO mice displayed an
increase in alpha cell mass (Fig. 6d), indicating that alpha cell
dysfunction is likely to be the major contributor to the pheno-
type displayed by PaskAKO mice.
The reasons for the differences in the impact on alpha
cell mass of global vs cell type-specific Pask deletion are
unclear. Furthermore, the above findings are in contrast to
earlier observations with global Pask-null animals [29], in
which fasting glucagon levels were higher in Pask-null
mice than in WT mice, and the ability of high glucose to
suppress glucagon secretion was impaired in islets from the
former. What may underlie these differences? Again,
actions of the kinase at extrapancreatic sites (such as liver,
adipocytes and brain) are one possibility, whilst a role for
PASK in restricting the production of alpha cell progeni-
tors, mooted above, may provide an alternative explana-
tion. In support of this idea, alpha cell mass was decreased
in global Pask-null mice (Fig. 4g). Alpha cell function is
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Fig. 7 Hyperinsulinaemic–
hypoglycaemic clamps in
PaskAKO and WT mice, and
release of glucagon from isolated
islets. Blood glucose levels
(a) and glucose infusion rate
(b) measured in PaskAKO
(dotted line) and WT littermates
(solid line) during insulin
(1.2 U kg−1 h−1) and glucose
(gluc, 20%) co-infusion 5 min
after bolus insulin infusion
(0 min). The glucose infusion rate
is indicated in (b). (c) Blood
glucagon measurement before
(0 min) and at the end (120 min)
of the clamp. Data are expressed
as means ± SEM; n= 3–5 mice
per genotype. (d) Glucagon
release from PaskAKO mouse
and control islets in response to
low (0.5 mmol/l) or high
(10 mmol/l) glucose (G).
(e) Insulin (0.75 U/kg, 0 min)
tolerance test on 24-week-old
male PaskAKO (n = 3; dotted
line) or WT (n= 5; solid line)
mice. *p< 0.05, **p < 0.01 by
Student’s t test with Bonferroni
correction
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also regulated through insulin secretion by neighbouring
beta cells and it is therefore conceivable that the effects
on glucagon secretion observed in the whole-body knock-
out mice may reflect a combination of defects in all pancre-
atic cell types in this model that are not replicated in the
present cell type-specific models. It is currently unknown,
for example, whether PASK has any function in pancreatic
delta cells, although somatostatin is a regulator of both al-
pha and beta cell function [42]. Nevertheless, the present
results demonstrate a clear and cell-autonomous role for
PASK in the acute control of glucagon secretion
(Fig. 7c, d) and beta cell mass (Fig. 5). The precise molec-
ular mechanisms through which the kinase acts will need
further exploration, and possibly the generation of mice
bearing selectively-labelled alpha cells to permit studies at
the single cell level [37].
Conclusions The present findings indicate that PASK plays
critical roles in the biology of both pancreatic beta and alpha
cells in vivo. However, we reveal striking differences between
the glycaemic phenotype of animals deleted globally for the
kinase vs the cell type-specific knockouts, demonstrating like-
ly important roles for tissue interactions or actions at early
developmental stages.
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